LEAMINGTON, ON, Feb. 1, 2018 /CNW/ - Aphria Inc. ("Aphria"
or the "Company") (TSX: APH or USOTCQB:
APHQF) confirms today that the Company is currently exploring
and considering strategic alternatives with respect to its US
cannabis related interests, including the possible divestiture of
its investments to strategic, long-term and committed investors in
the cannabis industry.
We have A Good Thing Growing.
About Aphria
Aphria Inc., one of Canada's
lowest cost producers, produces, supplies and sells medical
cannabis. Located in Leamington,
Ontario, the greenhouse capital of Canada. Aphria is
truly powered by sunlight, allowing for the most natural growing
conditions available. We are committed to providing
pharma-grade medical cannabis, superior patient care while
balancing patient economics and returns to shareholders.
For more information, visit www.Aphria.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward-looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, Aphria's ability to divest of its US cannabis
assets to any party and the timing of any divestiture of Aphria's
US cannabis assets. Forward-looking statements necessarily involve
known and unknown risks, including, without limitation, risks
associated with general economic conditions; adverse industry
events; marketing costs; loss of markets; future legislative and
regulatory developments involving medical cannabis or adult use of
cannabis; inability to access sufficient capital from internal and
external sources, and/or inability to access sufficient capital on
favourable terms; the medical cannabis industry in Canada or the United
States generally, income tax and regulatory matters; the
ability of Aphria to implement its business strategies;
competition; crop failure; currency and interest rate fluctuations
and other risks.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
SOURCE Aphria Inc.